earnings
confidence high
sentiment positive
materiality 0.80
Teva Q3 rev $4.3B (+13% YoY); raises FY2024 guidance; Austedo $435M (+28%)
TEVA PHARMACEUTICAL INDUSTRIES LTD
2024-Q3 EPS reported
-$1.26
revenue$12,315,000,000
- Q3 revenues $4.3B (+13% USD, +15% local currency); Non-GAAP diluted EPS $0.69 vs $0.60 YoY.
- Austedo US revs $435M (+28%); AJOVY global $137M (+21% local); Uzedy US $35M, FY outlook raised to ~$100M.
- Generics up 30% US, 8% Europe, 13% Int’l Markets (local currency); biosimilar to Prolia accepted by FDA/EMA.
- FY2024 guidance raised: rev $16.1-16.5B, Adj EBITDA $4.7-5.0B, Non-GAAP EPS $2.40-2.50.
- GAAP net loss $437M from $600M goodwill impairment and $450M legal provisions; cash from ops $693M.